Martin Currie Ltd. Sells 213,555 Shares of Illumina, Inc. $ILMN

Key Points

• Martin Currie Ltd. has reduced its stake in Illumina, Inc. by 97.4% in the first quarter, now holding only 5,743 shares worth approximately $456,000.
• Hedge funds and institutional investors currently own 89.42% of Illumina's stock, with several firms recently adjusting their positions.
• Illumina reported earnings of $1.19 per share for the most recent quarter, beating analyst expectations, but saw a 4.8% decline in revenue compared to the previous year.

Martin Currie Ltd. lowered its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 97.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,743 shares of the life sciences company's stock after selling 213,555 shares during the period. Martin Currie Ltd.'s holdings in Illumina were worth $456,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Townsquare Capital LLC lifted its holdings in shares of Illumina by 23.5% in the fourth quarter. Townsquare Capital LLC now owns 16,196 shares of the life sciences company's stock valued at $2,164,000 after purchasing an additional 3,087 shares in the last quarter. Sagespring Wealth Partners LLC purchased a new position in Illumina in the 4th quarter valued at about $225,000. Mariner LLC raised its holdings in Illumina by 13.5% in the 4th quarter. Mariner LLC now owns 10,921 shares of the life sciences company's stock valued at $1,459,000 after acquiring an additional 1,298 shares during the last quarter. CreativeOne Wealth LLC acquired a new stake in Illumina in the 4th quarter worth about $248,000. Finally, Jump Financial LLC raised its position in shares of Illumina by 260.0% in the 4th quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company's stock worth $1,051,000 after buying an additional 5,680 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of Illumina stock traded up $1.08 during trading on Tuesday, hitting $101.61. The stock had a trading volume of 1,024,499 shares, compared to its average volume of 2,350,199. The business has a fifty day moving average of $97.12 and a two-hundred day moving average of $89.34. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The firm has a market cap of $15.62 billion, a P/E ratio of 12.86, a PEG ratio of 2.25 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the company earned $0.36 EPS. Illumina's revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen lowered shares of Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Royal Bank Of Canada boosted their price objective on shares of Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Evercore ISI increased their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Robert W. Baird lifted their price target on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.